Differential expression of Fanconi anemia complementation group I in triple negative breast cancer.

Fanconi Anemia ◽

Triple Negative ◽

Complementation Group ◽

Primary Tumors ◽

Ductal Cells ◽

Group I

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding Fanconi anemia complementation group I, FANCI, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). FANCI was also differentially expressed in bulk tumor in human breast cancer (3). FANCI mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of FANCI in primary tumors of the breast was correlated with overall survival in patients with basal-like and luminal A type cancer, while within triple negative breast cancer, primary tumor expression of FANCI was correlated with overall survival in patients with immunomodulatory subtype disease. FANCI may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of cyclin A2 in triple negative breast cancer.

10.31219/osf.io/abq4x ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Ductal Cells ◽

Cyclin A2

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cyclin A2, CCNA2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CCNA2 was also differentially expressed in bulk tumor in human breast cancer (3). CCNA2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CCNA2 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CCNA2 was correlated with overall survival in patients with basal-like 1, basal-like 2, and mesenchymal subtype disease. CCNA2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of cell division cycle-associated 5 in triple negative breast cancer.

10.31219/osf.io/vxmz3 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cell Division ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cell division cycle-associated 5, CDCA5, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CDCA5 was also differentially expressed in bulk tumor in human breast cancer (3). CDCA5 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CDCA5 in primary tumors of the breast was correlated with overall survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of CDCA5 was correlated with overall survival in patients with mesenchymal subtype disease. CDCA5 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of NDC80, kinetochore complex component in triple negative breast cancer.

10.31219/osf.io/tbm6h ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Complex Component ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding NDC80, kinetochore complex component, NDC80, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). NDC80 was also differentially expressed in bulk tumor in human breast cancer (3). NDC80 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of NDC80 in primary tumors of the breast was correlated with overall survival in patients with basal-like and luminal A subtype cancer, while within triple negative breast cancer, primary tumor expression of NDC80 was correlated with overall survival in patients with basal-like 1 subtype disease. NDC80 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of cell division cycle associated 2 in triple negative breast cancer.

10.31219/osf.io/gmpxv ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cell Division ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cell division cycle associated 2, CDCA2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CDCA2 was also differentially expressed in bulk tumor in human breast cancer (3). CDCA2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CDCA2 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CDCA2 was correlated with overall survival in patients with basal-like 1, mesenchymal stem-like, and luminal androgen receptor subtype disease. CDCA2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of structural maintenance of chromosomes 4 in triple negative breast cancer.

10.31219/osf.io/nczr6 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Structural Maintenance Of Chromosomes

Primary Tumors ◽

Ductal Cells ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding structural maintenance of chromosomes 4, SMC4, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). SMC4 was also differentially expressed in bulk tumor in human breast cancer (3). SMC4 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of SMC4 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of SMC4 was correlated with overall survival in patients with mesenchymal, mesenchymal stem-like, and luminal androgen receptor subtype disease. SMC4 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2bo in triple negative breast cancer.

10.31219/osf.io/aphrb ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Significant Differential Expression ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bo, HIST1H2BO, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BO was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BO mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BO in primary tumors of the breast was correlated with overall survival in patients with basal-like and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BO was correlated with overall survival in patients with luminal androgen receptor subtype disease. HIST1H2BO may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of SPC25, NDC80 kinetochore complex component in triple negative breast cancer.

10.31219/osf.io/bywjs ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Complex Component ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding SPC25, NDC80 kinetochore complex component, SPC25, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). SPC25 was also differentially expressed in bulk tumor in human breast cancer (3). SPC25 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of SPC25 in primary tumors of the breast was correlated with overall survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of SPC25 was correlated with overall survival in patients with luminal androgen receptor subtype disease. SPC25 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of kinesin family member 2C in triple negative breast cancer.

10.31219/osf.io/9skva ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Family Member ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Ductal Cells ◽

Kinesin Family

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding kinesin family member 2C, KIF2C, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). KIF2C was also differentially expressed in bulk tumor in human breast cancer (3). KIF2C mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of KIF2C in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of KIF2C was correlated with overall survival in patients with mesenchymal and luminal androgen receptor subtype disease. KIF2C may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of RAD54-like in triple negative breast cancer.

10.31219/osf.io/kpg8z ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Significant Differential Expression ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding RAD54-like, RAD54L, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). RAD54L was also differentially expressed in bulk tumor in human breast cancer (3). RAD54L mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of RAD54L in primary tumors of the breast was correlated with overall survival in patients with basal-like and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of RAD54L was correlated with overall survival in patients with basal-like 1 subtype disease. RAD54L may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of anti-silencing function 1B histone chaperone in triple negative breast cancer.

10.31219/osf.io/t4kn7 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Histone Chaperone ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding anti-silencing function 1B histone chaperone, ASF1B, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). ASF1B was also differentially expressed in bulk tumor in human breast cancer (3). ASF1B mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of ASF1B in primary tumors of the breast was correlated with overall survival in patients with HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of ASF1B was correlated with overall survival in patients with basal-like 2 subtype disease. ASF1B may be of relevance to initiation, maintenance or progression of triple negative breast cancers.